Mixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
31 08 2022
Historique:
pubmed: 9 8 2022
medline: 9 9 2022
entrez: 8 8 2022
Statut: ppublish

Résumé

Dermatitis is the most common adverse event during treatment with benznidazole in chronic Chagas disease and is probably mediated by T cells. A set of molecules representative of the different type IV hypersensitivity reactions was evaluated in the circulation and skin biopsies of Trypanosoma cruzi-infected subjects presenting dermatitis during benznidazole administration. Through cytometric bead assays and enzyme-linked immunosorbent assay capture techniques, the serum levels of cytokines, chemokines, proapoptotic molecules, and mediators of the activation and migration of eosinophils and T cells were measured in subjects infected with Trypanosoma cruzi who exhibited skin adverse events (

Identifiants

pubmed: 35938810
doi: 10.1128/spectrum.01357-22
pmc: PMC9430713
doi:

Substances chimiques

Nitroimidazoles 0
benzonidazole YC42NRJ1ZD

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0135722

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI110346
Pays : United States

Références

J Infect Dis. 2004 Mar 1;189(5):909-18
pubmed: 14976609
Allergy. 2009 Sep;64(9):1269-78
pubmed: 19254289
Clin Ter. 2019 Jan-Feb;170(1):e55-e60
pubmed: 30789198
Clin Microbiol Infect. 2022 Jun;28(6):881.e1-881.e5
pubmed: 34863919
Ann Intern Med. 2003 Oct 21;139(8):683-93
pubmed: 14568857
Annu Rev Med. 2015;66:439-54
pubmed: 25386935
J Exp Med. 1995 Jan 1;181(1):71-7
pubmed: 7528780
J Immunol. 2006 Apr 1;176(7):4431-9
pubmed: 16547281
Nat Rev Immunol. 2015 Feb;15(2):104-16
pubmed: 25614320
Allergy. 2004 Aug;59(8):793-805
pubmed: 15230810
Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):270-5
pubmed: 9419365
Expert Rev Anti Infect Ther. 2009 Mar;7(2):157-63
pubmed: 19254164
Clin Infect Dis. 2015 Dec 1;61(11):1688-94
pubmed: 26265500
Br J Clin Pharmacol. 2011 May;71(5):672-83
pubmed: 21480947
Int J Mol Sci. 2021 Feb 16;22(4):
pubmed: 33669428
Immunol Allergy Clin North Am. 2009 Aug;29(3):537-54
pubmed: 19563996
Allergy. 2004 Jun;59(6):613-22
pubmed: 15147446
Drug Saf. 2000 Dec;23(6):483-507
pubmed: 11144658
Cardiovasc Pathol. 2017 Jul - Aug;29:1-6
pubmed: 28433861
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32571827
J Interferon Cytokine Res. 2020 Apr;40(4):172-181
pubmed: 32195616
Handb Exp Pharmacol. 2010;(196):29-55
pubmed: 20020258
Antimicrob Agents Chemother. 2015 Nov 23;60(2):833-7
pubmed: 26596935
Antimicrob Agents Chemother. 2010 Nov;54(11):4896-9
pubmed: 20823286
Clin Exp Allergy. 2001 Sep;31(9):1398-408
pubmed: 11591190
J Clin Invest. 2004 Mar;113(5):701-8
pubmed: 14991068
Pediatrics. 2011 Jan;127(1):e212-8
pubmed: 21173000
Front Immunol. 2017 Sep 11;8:1122
pubmed: 28955339
J Allergy Clin Immunol Pract. 2020 Oct;8(9):3198-3200.e3
pubmed: 32417447
Curr Opin Allergy Clin Immunol. 2015 Aug;15(4):294-9
pubmed: 26110678
Trans R Soc Trop Med Hyg. 2012 Oct;106(10):636-8
pubmed: 22898619
Allergy. 2008 Feb;63(2):181-8
pubmed: 18005225
Contact Dermatitis. 2018 Aug;79(2):105-106
pubmed: 29635801
Braz J Infect Dis. 2007 Aug;11(4):411-4
pubmed: 17873995
J Antimicrob Chemother. 2021 May 12;76(6):1580-1592
pubmed: 33693664
Cell. 2000 Mar 17;100(6):655-69
pubmed: 10761931
J Immunol Methods. 2009 Jan 1;340(1):33-41
pubmed: 18952093
Nat Rev Nephrol. 2013 May;9(5):255-65
pubmed: 23507826
Br J Dermatol. 2016 Sep;175(3):604-7
pubmed: 26851874
Nat Rev Immunol. 2013 Nov;13(11):777-89
pubmed: 24113868
Semin Immunopathol. 2021 Jun;43(3):393-409
pubmed: 34097126
Antimicrob Agents Chemother. 2014 Nov;58(11):6371-7
pubmed: 25114135
Front Pharmacol. 2019 May 21;10:469
pubmed: 31164819
J Invest Dermatol. 2002 Apr;118(4):728-33
pubmed: 11918724

Auteurs

Melisa D Castro Eiro (MD)

Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.
Instituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.

María A Natale (MA)

Instituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.

María G Alvarez (MG)

Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.

Araceli Castro (A)

Instituto de Medicina Traslacional, Trasplante y Bioingeniería (IMeTTyB), Universidad Favaloro-CONICET, Buenos Aires, Argentina.

Débora Seigelshifer (D)

Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.

Rodolfo Viotti (R)

Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.

Marisa Fernández (M)

Instituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.

Luis Mazzuoccolo (L)

Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.

Bruno Lococo (B)

Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.

Graciela L Bertocchi (GL)

Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.

Gonzalo Cesar (G)

Instituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.

María C Albareda (MC)

Instituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.

María J Elias (MJ)

Instituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.

María B Caputo (MB)

Instituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.

Eduardo Gaddi (E)

Hospital Pedro de Elizalde, Buenos Aires, Argentina.

Jeanette Balbaryski (J)

Hospital Pedro de Elizalde, Buenos Aires, Argentina.

Carlos A Vigliano (CA)

Instituto de Medicina Traslacional, Trasplante y Bioingeniería (IMeTTyB), Universidad Favaloro-CONICET, Buenos Aires, Argentina.

Susana A Laucella (SA)

Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.
Instituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH